Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial to Evaluate the Efficacy and Safety of AQX-1125 (200 mg) in Male Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Next Previous
Trial Profile

A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial to Evaluate the Efficacy and Safety of AQX-1125 (200 mg) in Male Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rosiptor (Primary)
  • Indications Pelvic pain; Prostatitis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Aquinox Pharmaceuticals

Most Recent Events

  • 27 Jun 2018 Status changed from recruiting to discontinued, as reported in an Aquinox Pharmaceuticals media release
  • 11 Jun 2018 According to an Aquinox Pharmaceuticals media release, dosing has been initiated.
  • 11 Jun 2018 Status changed from not yet recruiting to recruiting, according to an Aquinox Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top